waynesworld, I can't help but view the notion of a "re-rating" as being linked to a company share price. The company seems more "de-risked", as you've said, with this new deal (although we do not know what the terms are and are unlikely to know due to the nature of biotech secrets). We are unlikely to go broke now, and have to turn to the likes of La Jolla, our Aussie biotech bain. On the other hand, I see re-rating as implying an upward move of the SP, and one that is sustainable and normative. I look forward to that. Indeed, I am uncertain as to why this is not the case now- Nick said it was our biggest deal ever.
I don't think any holder would be derisive about the current share price: that would involve at least a little mirth, if disdainful. No-one is laughing.
PYC Price at posting:
3.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)